dual nature of the electrophysiologic actions of the drug. However, the difference is that quinidine is clearly an antifibrillatory (in the atria) and antiarrhythmic (in the ventricles where it suppresses premature ventricular contractions) agent. Not too long after it was introduced, quinidine was found to increase the refractory period in cardiac tissues and in the 1950s it was found to prolong repolarization as well as to slow conduction (2) . Which of these two electrophysiologic actions might be primarily responsible for the drug's observed effects on the refractory period and thus for its antiarrhythmic actions? The classic report of the congenital long QT interval syndrome in 1957 (3) , demonstrating a causal relationship between proarrhythmic propensity and lengthening of the action potential duration, cast doubt on the validity of prolonged repolarization as a major antiarrhythmic action. It clearly had the effect of shifting attention away from prolonged repolarization as a major antiarrhythmic mechanism. Such a shift was further bolstered in 1964 by the report (4) of the drug producing syncope ("quinidine syncope") due to what was termed torsades de pointes (5) . From the standpoint of overall antiarrhythmic drug development, these observations led to a focus on the local anesthetic effect of quinidine in cardiac muscle and away from its proclivity to prolong repolarization. Attention was therefore sharply drawn to the suppressant effects of other conduction blockers, such as lidocaine and its oral congeners mexilitine and tocainide, which were subsequently synthesized.
Lidocaine became the focal point of the suppressant approach especially in the setting of the coronary care unit in the early 1960s. Indeed, it provided the roadmap for the development of new antiarrhythmic compounds. The search for more potent conduction blockers began in earnest. The efforts culminated in the development of a host of conduction blockers including flecainide, encainide, and propafenone among others, all-powerful premature ventricularcontraction suppressants. Derivatives of drugs that had "quinidine-like properties" (having dual properties of slowing conduction and prolonging repolarization) such as procainamide and disopyramide thus were not favored as potential antiarrhythmics for synthesis and development.
In the midst of these developments, it was discovered (6-8) that two unique antianginal compoundssotalol and amiodarone-had the property of prolonging cardiac repolarization; sotalol after acute drug administration and amiodarone after a defined period of chronic therapy, respectively. Both were found to be reasonably potent inhibitors of sympathetic excitation, sotalol a n-blocker and amiodarone a coronary vasodilator with the associated property for nonspecific sympathetic antagonism. However, neither amiodarone nor sotalol had potent local anesthetic effects in cardiac muscle, but their effects on repolarization were substantial. On the other hand, the effect on the action potential duration did correlate with significant antifibrillatory actions in experimental animals models (6) . A similar correlation was found for a variety of 5-blocking drugs, which unlike sotalol or amiodarone, did not lengthen repolarization, nor did they block sodium-mediated myocardial conduction (6, 9) . Thus, experimental data in the early 1970s (6-11) provided strong support for the hypothesis that 3-blockade per se constituted a major and discrete class of antiarrhythmic and antifibrillatory actions.
Three decades later, an extensive clinical database on the effects of ,3-blockade on mortality has been created. The data stemmed from increasingly elegant large placebo-controlled clinical trials in a wide spectrum of patients with cardiac disease. The earlier data have been summarized by Yusuf and associates (12) , and the more recent data have been placed in perspective by Reiter (13) . The quantitative data are compelling with regard to the beneficial effects of P-blockade on sudden death, cardiac death, as well as total mortality. In the year 2001, it is clearly safe to conclude that the clinical utility of the antiarrhythmic and antifibrillatory effects of n-blockade has at last come of age.
The evidence that ,-blockers prolong survival in many subsets of patients both with manifest arrhythmias as well as in those at high risk for arrhythmic deaths is persuasive. The critical issue here is whether the overall benefit on survival is due largely to antiarrhythmic and antifibrillatory actions or whether the observed reduction in mortality stems from other properties of this class of drugs. It is known that ,blockers may favorably influence mortality by their indirect effects such as limiting myocardial infarct size or by exerting anti-ischemic effects in patients with coronary artery disease (13) . Unlike conventional antiarrhythmic drugs, ,-blockers are not powerful suppressants of premature ventricular contractions (PVCs) or ventricular tachycardia or fibrillation (VT/VF) induced by programmed electrical stimulation. Can they still prevent VTIVF (the immediate cause of sudden death in many patients with heart disease) by other antifibrillatory mechanisms? The data on this issue is now compelling. For example, it is known that the electrophysiologic consequences of sympathetic hyperactivity may lead to the shortening of refractory period, an increase in ventricular automaticity, and a decrease in VF threshold. Decreasing sympathetic influences to the heart (14, 15) attenuates such effects. Therefore, it was not entirely unexpected when it was found that, as a class, 3-adrenergic blocking drugs prevented the development of VTNF in experimental models (6).
3-blockers have been found to be effective in reducing mortality in many subsets of patients with manifest arrhythmias and in those at high risk for dying from arrhythmic deaths (16) (17) (18) (19) (20) (21) (22) (23) . They reduced death rate in patients in survivors of cardiac arrest (24), in those with congenital long QT interval syndrome (25, 26) , and in selected cases of ventricular tachycardia (27) (28) (29) . These findings have not all been from controlled clinical trials. Nevertheless, they are in line with the data from a plethora of randomized, placebocontrolled beta-blocking trials. Trial data from over 50,000 patients now attest to the consistent and significant decreases in mortality, especially in survivors of acute myocardial infarction (16) (17) (18) (19) (20) (21) (22) (23) . What are the lessons from these f-blocker mortality trials in survivors of acute myocardial infarction? Undoubtedly, the reduction in arrhythmia mortality as judged by the reduced incidence of sudden death, and total mortality alongside the consistent and significant reduction in the incidence of myocardial reinfarction is almost overwhelming in its consistency (16) (17) (18) (19) (20) (21) (22) (23) . However, some features need further emphasis with regard to therapeutic implications. The uniformity of the data now must mandate the routine use of ,3-blockade in the survivors of myocardial infarction in patients in whom there are no contraindications. Of particular interest, is the observation that the magnitude of benefit on mortality in the prophylactic trials correlated closely to the degree of reduction in heart rate (30) . It provides therapeutic guidelines in judging dosage n-Blockers as Antiarrhythmic and Antifibrillatory Drugs * Singh 109 without resorting to the measurement of serum drug levels for optimal therapy. It is also known that agents that fail to depress the heart rate significantly because of their agonist actions had minimal or no effect on mortality. In other respects the favorable effect is clearly a class effect.
The substudy of the 3-Blocker Heart Attack Trial (BHAT) in postmyocardial infarct survivors provided an important observation. It indicated that the extent of benefit with respect to mortality increased commensurately with the reduction in the degree of fall in the left ventricular ejection fraction (31) , there being lesser degrees of benefit in patients with relatively well-preserved ventricular function. A percentage of the patients in this substudy had congestive cardiac failure. The BHAT substudy (31) and other observations of a pilot nature (32) subsequently led to a number of larger placebo-controlled trials with various fBblockers in patients with congestive cardiac failure (33) (34) (35) (36) (37) (38) (39) . The data have been most definitive in the case of CIBIS 11 (37) , MERIT-HF (38) , and COPER-NICUS (9) . The test agents (and the number of patients enrolled) used in these studies were bisoprolol (n=2647), metoprolol CR/XL (n=3991), and carvedilol (n=2289), respectively. The total mortality reduction by these three agents were 34% (p=0.0001), 34% (p=0.0062), and 35% (p=0.0003) respectively at 1 year and overall sudden death rate was approximately 40% in each of the trials. There were significant increases in the left ventricular ejection fraction and there was a reduction in the hospitalization in all three trials when compared to placebo. Thus, as in the case of the patients in the Post-MI setting, it was evident that 5-blockade exerted a consistent and clinically meaningful reduction in total mortality and in sudden death in patients with cardiac failure, even in those with the most advanced. These trial outcomes have important therapeutic implications. From the mechanistic point of view, they are likely to prove the most effective antiarrhythmic or antifibrillatory compounds for mortality reduction in this clinical setting. The data have a bearing on the fundamental reorientation of antiarrhythmic therapy in patients with severe cardiac disease (40) .
As in the case of the high risk patients after myocardial infarction, ,8-blockers should not be withheld in patients with cardiac failure but therapy with the drugs needs to be initiated at low doses and increased in a stepwise fashion to attain optimal dosage as a function of time. 3-blockers are rapidly and justifiably becoming routine therapy for most patients with congestive heart failure, and it is unlikely that future trials with this class of compounds will be performed against a placebo control. It is noteworthy that there are significant differences among the effective compounds discussed in this editorial, but their precise significance remains to be defined.
The effects of ,-blockers on total mortality in most subsets of patients in which they are effective are likely to be additive to those of angiotensin-converting enzyme inhibitors and possibly synergistically with those of other agents such as amiodarone. Such a synergism may raise the issue whether in certain subsets of patients the impact on mortality of the combination therapy might rival or even exceed those of the implantable cardioverter defibrillators. These considerations are based on expansive data on the impact of a number of classes of antiischemic, antiarrhythmic, and antifailure drugs. They pose significant challenges to the investigator for the design and execution of mortality trials using combination therapy aimed at prolonging survival in patients at the highest risk for arrhythmic deaths. Whatever the outcome of such trials, it is now clear that the findings from trials such as the CIBIS II, MERIT-HF, and COPERNICUS confirm that ,B-adrenergic drugs may be the most effective agents for inducing the most consistent reduction in total mortality and sudden death in patients with ischemic and nonischemic cardiac disease associated with impaired ventricular function and cardiac failure. Such an effect may be mediated largely by way of their antiarrhythmic and antifibrillatory actions.
